Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Carcinoma, Hepatocellular 115Cholangiocarcinoma 24Carcinoma, Renal Cell 20Liver Neoplasms 12Stomach Neoplasms 10Biliary Tract Neoplasms 10Thyroid Neoplasms 8Endometrial Neoplasms 8Breast Neoplasms 8Neoplasms 7Recurrence 6Neuroendocrine Tumors 5Neoplasm Metastasis 5Melanoma 5Uterine Cervical Neoplasms 4Thyroid Carcinoma, Anaplastic 4Thyroid Cancer, Papillary 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Diseases 3Cirrhosis, Familial, with Pulmonary Hypertension 3Carcinoma, Adenoid Cystic 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Adenocarcinoma 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2

Interventions

Cisplatin 101Radiotherapy 53Brachytherapy 41Paclitaxel 37Carboplatin 36Surveys and Questionnaires 28Blood Specimen Collection 20pembrolizumab 19Radiation 17Magnetic Resonance Spectroscopy 17Drug Therapy 17Colposcopy 16Methods 14Bevacizumab 14Early Intervention, Educational 12toripalimab 11Topotecan 11Radiotherapy, Intensity-Modulated 11Papanicolaou Test 11Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 11Chemoradiotherapy 11Biopsy 11camrelizumab 10Mass Screening 10Gemcitabine 10Patient Navigation 9Papillomavirus Vaccines 9Nivolumab 9Fluorodeoxyglucose F18 9Educational Status 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Uterine Cervical Neoplasms × lenvatinib × Clear all
NCT06266338 2026-05-06

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

University of Texas Southwestern Medical Center

Phase 2 Recruiting
30 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
30 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Erasmus Medical Center

Phase 2 Not yet recruiting
87 enrolled
Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms

NCT04865887 2025-10-07

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Georgetown University

Phase 2 Recruiting
35 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡